Having dominated the NGS-based HLA Typing landscape in Europe for the past several years, the growth Omixon has observed outside of Europe, fueled by adoption in the African continent, Russia and multiple labs in the Middle East has been particularly satisfying.
BUDAPEST, Hungary and CAMBRIDGE, Mass. (PRWEB) May 07, 2018
Global molecular diagnostics company Omixon, headquartered in Budapest with US offices in Cambridge, MA, announce today that Holotype HLA and other Omixon products will be featured in nine poster presentations produced by Holotype customers at the annual meeting of the European Federation for Immunogenetics (EFI) in Venice, Italy. Additionally, Omixon’s Lunch Symposium on Thursday will focus on the experiences of existing Holotype HLA for clinical and registry purposes within and outside the European Union.
The power of Holotype HLA will be demonstrated in several posters, including the identification of novel null alleles; Mette Christiansen et al. (P30) who detected a novel substitution in HLA-B*08, Vera Siffnerova et al. (P87) who used the unique phasing capabilities of Holotype HLA to resolve a novel HLA-C*02 unresolvable by SBT and Amalia Dinou (P146) who showed that HLA Twin could resolve a phasing ambiguity as HLA-B*44:18, 50:01, that was previously unresolvable by other methods. Of special interest is the poster from Eszter Lazar-Molnar (P115), who investigated challenging samples with Loss of Heterozygosity (LoH) in Acute Myeloid Leukemia (AML) - important for understanding the evolution of tumor escape from immune response. In these intriguing samples, the unique capabilities and features of Holotype HLA and HLA Twin were used to determine the HLA types even in situations of extreme imbalance (~10%) in the DNA sample due to LoH.
Omixon’s Lunch Symposium, titled “HLA Typing without Borders” on May 10 will feature three customer experience stories from within and outside Europe. Vera Siffnerova from the UHKT in Prague will present on their experience with Holotype HLA V2 for stem cell transplantation, while Dr. Elena Shagimardanova from Kazan Federal University in Russia will present on their role as Russian pioneer in the implementation of Holotype HLA and NGS for HLA registry typing and Derrick Nelson from the South African National Blood Service will present on the improvements between the Holotype HLA V1 and v2 as they look to scale up their stem cell typing to 6,000 samples per year for registry typing. Omixon’s CEO Dr. Peter Meintjes will finish the session with announcements about the continuous improvements to Holotype HLA, including the timeline for launching Holotype HLA v3 as RUO and CE-IVD, and two new primer kit products for ABO Blood Group Typing and MICA genotyping.
Marcello Scala, VP Sales, EMEA & Asia Omixon says, “Having dominated the NGS-based HLA Typing landscape in Europe for the past several years, the growth Omixon has observed outside of Europe, fueled by adoption in the African continent, Russia and multiple labs in the Middle East has been particularly satisfying. We are delighted by the continued enthusiasm that customers have for Holotype HLA to support their workflows for bone marrow transplantation, solid organ transplantation and registry typing and how frequently our products and our people are recommended to new labs wishing to adopting this exciting technology”.
Omixon at EFI 2018
May 09 - May 12 | Omixon will be exhibiting at Booth #15/16 throughout the conference
May 09 - May 12 | HLA Twin Live Software Demos at Booth #15/16
May 09, 9am - 12pm | Distributor Workshop
May 09, 1pm - 5pm | Interactive User Group Meeting
May 10, 1.30pm-2.30pm | Holotyping Without Borders – Holotype HLA v2 Experiences Within and from Outside the EU for the Benefit of the Wider Transplant Community
Omixon Featured in Posters
P30 | Mette Christiansen et al. (2018) - Discovery of a novel HLA-B*08 null allele in a danish kidney transplant recipient
P87 | Vera Siffnerova et al. (2018) - Detection of a novel allele with NGS has never been easier
P115 | Eszter Lazar-Molnar et al. (2018) - Loss of heterozygosity in the HLA region and sensitivity of HLA typing methods for detecting underrepresented alleles
P135 | Mehdi Alizadeh et al. (2018) - From the sample to donor / recipient compatibility: A comprehensive range of laboratory reagents and equipment for NGS-based genotyping of classical and non-classical HLA genes
P146 | Amalia Dinou et al. (2018) - Definitive resolution of HLA typing errors and ambiguities by NGS typing
P165 | Thomas M.C. Binder et al. (2018) - A new unusual HLA-DQA1 allele: DQA1*01Q:NEW
P168 | Stana Tokić et al. (2018) - HLA-A, -B, -C, -DRB1, -DQA1, -DQB1 AND -DPB1 allele and haplotype frequencies defined by Next generation Sequencing in a population of East Croatia blood donor
P172 | Thomas M.C. Binder et al. (2018) - HLA-DRB1*03:24 – A DRB1*03:01-like Exon 2 sequence in typical DRB1*13:02- haplotype
Omixon is a global molecular diagnostics company, headquartered in Budapest, Hungary, with US offices in Cambridge, MA that commercializes disruptive technologies for clinical and research laboratories. Omixon’s flagship product, Holotype HLA, is the world’s leading NGS-based HLA genotyping product that delivers the most accurate high-resolution HLA genotyping available, and is used in more than 45 hospitals worldwide. Omixon’s research software, HLA Explore analyzes data from any sequencing technology and determines HLA genotypes from Whole Exome/Genome Sequencing experiments. Omixon maintains an active grant-funded research program with a product pipeline focused on pre- and post-transplantation, and HLA genotyping applications beyond transplantation. For more information, visit http://www.omixon.com